Regeneron Pharmaceuticals Inc (REGN)

Quick ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash US$ in thousands 2,730,000 2,152,300 1,937,200 3,916,300 3,105,900 3,491,300 3,395,100 3,345,700 2,885,600 3,432,400 2,072,200 1,437,900 2,193,700 1,573,000 1,992,200 2,208,200 1,617,800 1,384,800 1,045,500 1,708,500
Short-term investments US$ in thousands 8,114,800 7,761,300 6,990,500 5,043,400 4,636,400 3,530,400 4,171,300 3,704,900 2,809,100 2,355,200 1,838,600 2,065,900 1,393,300 1,452,900 1,152,000 1,795,200 1,596,500 1,493,100 1,624,200 1,523,900
Receivables US$ in thousands 5,667,300 5,584,500 5,121,300 5,118,600 5,328,700 5,548,300 5,161,400 4,839,000 6,036,500 5,452,000 6,998,600 4,173,000 3,111,500 3,553,300 2,380,200 2,531,400 2,360,600 2,373,100 2,172,200 2,016,000
Total current liabilities US$ in thousands 3,423,400 3,598,600 3,104,400 3,100,100 3,141,300 2,879,200 3,033,900 3,007,600 3,932,500 3,714,800 3,732,400 3,217,800 2,697,400 2,337,800 3,702,400 2,055,200 2,096,600 1,765,400 1,713,100 1,511,400
Quick ratio 4.82 4.31 4.53 4.54 4.16 4.37 4.20 3.95 2.98 3.03 2.92 2.39 2.48 2.81 1.49 3.18 2.66 2.97 2.83 3.47

December 31, 2023 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($2,730,000K + $8,114,800K + $5,667,300K) ÷ $3,423,400K
= 4.82

The quick ratio of Regeneron Pharmaceuticals, Inc. has been consistently high over the past eight quarters, ranging from 4.09 to 4.94. This indicates that the company has a strong ability to meet its short-term obligations using its most liquid assets. A quick ratio above 1 typically suggests that the company is capable of covering its current liabilities with its quick assets, such as cash, marketable securities, and accounts receivable, which are readily convertible into cash.

The upward trend in the quick ratio from Q1 2022 to Q4 2023 indicates an improvement in Regeneron's liquidity position. This trend suggests that the company has been effective in managing its short-term assets and liabilities, maintaining a healthy financial position.

Overall, the consistently high quick ratio of Regeneron Pharmaceuticals, Inc. reflects a robust liquidity position, which can contribute to the company's ability to fund its operations, invest in growth opportunities, and weather potential financial challenges.


Peer comparison

Dec 31, 2023


See also:

Regeneron Pharmaceuticals Inc Quick Ratio (Quarterly Data)